Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds SAQsgenetics-dysmorphology-and-metabolism

Paeds SAQs · genetics-dysmorphology-and-metabolism

Marfan syndrome and heritable connective-tissue disorders — formative SAQs

Formative SAQs on Marfan syndrome and the heritable connective-tissue disorders: recognising the marfanoid phenotype, confirming with the revised Ghent nosology and FBN1 sequencing, distinguishing Marfan from Loeys-Dietz, vascular and hypermobile Ehlers-Danlos, Beals and homocystinuria by gene and lens direction, and applying the lifelong aortic-root surveillance and treatment plan.

20 marks30 min1 min readVerification in progress

Target exams

RACP General PaediatricsMRCPCH ClinicalRACP DWE
On this page
Study tools

Target exams

RACP General PaediatricsMRCPCH ClinicalRACP DWE
Prompt
Marfan syndrome and the heritable connective-tissue disorders across the lifespan

SAQ 1 (10)

A 14-year-old boy presents with tall stature, a pectus carinatum, a positive wrist-and-thumb sign, and an echocardiogram showing aortic-root dilation at the sinuses of Valsalva. Slit-lamp examination shows superotemporal lens subluxation. There is no relevant family history. [2] [1]

a) State the diagnosis and the cardinal features that confirm it under the revised Ghent nosology. Explain why a karyotype is not the confirmatory test. (3 marks) [2]

b) Explain the two-arm pathophysiology (structural and signalling) and name the molecular discovery that reframed the disease. (3 marks) [3] [1]

c) Outline the lifelong management plan, naming the medical therapy and the result of the Pediatric Heart Network atenolol-versus-losartan trial. (3 marks) [4] [1]

d) Both parents are clinically unaffected. State the recurrence risk for the next child and explain the reasoning, including the role of cascade testing. (1 mark) [1] [2]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References5ShowHide
  1. [1]Dietz H FBN1-related Marfan syndrome. GeneReviews, 1993.PMID 20301510
  2. [2]Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet, 2010.PMID 20591885
  3. [3]Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet, 2003.PMID 12598898
  4. [4]Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med, 2014.PMID 25405392
  5. [5]MacCarrick G, Black JH, Bowdin S, El-Hamamsy I, Frischmeyer-Guerrerio PA, Guerrerio AL, et al. Loeys-Dietz syndrome: a primer for diagnosis and management. Genet Med, 2014.PMID 24577266
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousLysosomal storage disorders — formative SAQsgenetics-dysmorphology-and-metabolismNextMitochondrial diseasegenetics-dysmorphology-and-metabolism